Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Model of translational cancer research in multiple myeloma.
Yasui H, Ishida T, Maruyama R, Nojima M, Ikeda H, Suzuki H, Hayashi T, Shinomura Y, Imai K. Yasui H, et al. Among authors: imai k. Cancer Sci. 2012 Nov;103(11):1907-12. doi: 10.1111/j.1349-7006.2012.02384.x. Epub 2012 Aug 17. Cancer Sci. 2012. PMID: 22809142 Free PMC article. Review.
Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
Kubo T, Tsurita G, Hirohashi Y, Yasui H, Ota Y, Watanabe K, Murai A, Matsuo K, Asanuma H, Shima H, Wada S, Nakatsugawa M, Kanaseki T, Tsukahara T, Mizuguchi T, Hirata K, Takemasa I, Imai K, Sato N, Torigoe T. Kubo T, et al. Among authors: imai k. Cancer Sci. 2019 Aug;110(8):2386-2395. doi: 10.1111/cas.14099. Epub 2019 Jul 11. Cancer Sci. 2019. PMID: 31206934 Free PMC article. Clinical Trial.
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, Hayashi H, Miyakoshi T, Watanabe K, Murai A, Asanuma H, Tokita S, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nakae Y, Sugita O, Ito YM, Ota Y, Kimura Y, Kutomi G, Hirata K, Mizuguchi T, Imai K, Takemasa I, Sato N, Torigoe T. Shima H, et al. Among authors: imai k. Cancer Sci. 2019 Aug;110(8):2378-2385. doi: 10.1111/cas.14106. Epub 2019 Jul 23. Cancer Sci. 2019. PMID: 31218770 Free PMC article. Clinical Trial.
Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma.
Aoki Y, Nojima M, Suzuki H, Yasui H, Maruyama R, Yamamoto E, Ashida M, Itagaki M, Asaoku H, Ikeda H, Hayashi T, Imai K, Mori M, Tokino T, Ishida T, Toyota M, Shinomura Y. Aoki Y, et al. Among authors: imai k. Genome Med. 2012 Dec 22;4(12):101. doi: 10.1186/gm402. eCollection 2012. Genome Med. 2012. PMID: 23259664 Free PMC article.
Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Nojima M, Maruyama R, Yasui H, Suzuki H, Maruyama Y, Tarasawa I, Sasaki Y, Asaoku H, Sakai H, Hayashi T, Mori M, Imai K, Tokino T, Ishida T, Toyota M, Shinomura Y. Nojima M, et al. Among authors: imai k. Clin Cancer Res. 2009 Jul 1;15(13):4356-64. doi: 10.1158/1078-0432.CCR-08-3336. Epub 2009 Jun 23. Clin Cancer Res. 2009. PMID: 19549772
5,182 results